title: Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
abstract: The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas. No responses were seen in 18 evaluable patients. Toxicity consisted mainly of nausea/vomiting. It is concluded that oral miltefosine has no activity in soft tissue sarcoma.
authors.affiliation: Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: K
authors.initials: K
authors.lastname: Krzemieniecki
authors.forename: T
authors.initials: T
authors.lastname: Kok
authors.forename: A
authors.initials: A
authors.lastname: Poveda
authors.forename: C
authors.initials: C
authors.lastname: van Pottelsberghe
authors.forename: M
authors.initials: M
authors.lastname: van Glabbeke
authors.forename: H
authors.initials: H
authors.lastname: Mouridsen
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
chemical_list: D010767:Phosphorylcholine; C039128:miltefosine